The development and application of antibodies targeting PD-1 (nivolumab and pembrolizumab) and PD-L1 (atezolizumab, avelumab, and durvalumab) have advanced the treatment of melanoma [3], nonsmall cell lung cancer (NSCLC) [4], renal cell cancer [5], colorectal cancer [6], and head and neck cancer [7]. This evidence concerns the gene PDCD1 and melanoma.